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Abstract
Background: Diabetes is quickly becoming the most widespread disorder in the Western world. Among the most
prevalent effects of diabetes is atherosclerosis, which in turn is driven in part by inflammation. Both insulin and
Tumor Necrosis Factor-alpha (TNFα) increase the presence of Vascular Cellular Adhesion Molecule-1 (VCAM-1)
expression. The aim of this study is to determine the effects of downregulating Extracellular signal-Regulated
Kinase-2 (ERK2) and Akt on insulin and TNFa-stimulated VCAM-1 expression.
Methods: Here we begin to define the relationships between ERK2 and Akt regulation of insulin and TNFα-stimulated
VCAM-1 expression in Rat Arterial Endothelial Cells (RAEC) by transfecting RAEC with ERK2 and Akt RNA interference
(RNAi) and then treating these cells with insulin (10 nM) or TNFα (10 ng/mL) alone or in combination.
Results: Western blot analyses, flow cytometry and confocal microscopy were used to determine changes in VCAM-1
expression within the above-stated parameters. Cells transfected with ERK2 or Akt RNAi plasmids increased insulin and
TNFα-stimulated VCAM-1 total protein expression significantly (P < 0.05) greater than that seen in mock transfected
cells and expressed cell surface VCAM-1 greater than that seen in mock transfected cells as indicated by flow
cytometry and confocal microscopy. Nevertheless, the decrease of both kinases did not increase insulin or
TNFα-stimulated VCAM-1 expression above that seen when one or the other RNAi was present.
Conclusions: Taken together, our results demonstrate that ERK2 and Akt may be negative regulators of
insulin and TNF-α stimulated VCAM-1 and that their loss or down regulation might upregulate VCAM-1
expression and contribute to vascular disease.
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Background
Diabetes mellitus (DM) is a serious global health
problem. In 2014, 29.1 million adults were clinically
diagnosed with diabetes and $245 billion dollars were
spent on the treatment for diabetes in the United States
(US) alone. Diabetes brings along with it a sequela of
adverse conditions such as, but not limited to, insulin
resistance, dyslipidemia, retinopathy, nephropathy, and
cardiovascular disease (CVD) [1]. CVD is among the
most aggressive aspects of DM and is associated with
plaque formation, decreased blood flow rate, thrombosis,
occlusion and rupture of the arteries, morbidity and
mortality [2].
Atherosclerosis has been linked to a range of cellular
and molecular changes in the vascular wall most of
which are noted in the endothelial cells of the arteries
[3]. Associated with the remodeling of the arterial walls
is the expression of the endothelial surface molecule,
Vascular Cell Adhesion Molecule-1 (VCAM-1) [4].
VCAM-1 appears to be upregulated in DM patients’
endothelial cells. The increase of VCAM-1 appears to
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foster the recruitment of monocytes to the surface of the
endothelium and their subsequent transmigration across
the endothelial layer [5]. Once embedded into the vascu-
lar smooth muscle layer, these monocytes mature to fully
functional macrophages, which subsequently activate
and express inflammatory cytokines such as Tumor
Necrosis Factor-alpha (TNFα) [4].
Hyperinsulinemia (HI) and increased presence of
TNFα are consequences of insulin resistance [1, 6]. Both
HI and TNFα in turn exacerbate the pathophysiological
conditions of the endothelium and cause an increase in
VCAM-1 expression. Expression of VCAM-1 is regu-
lated by a family of kinases, which mediate external sig-
nals to internal events [7, 8]. These kinases include, but
are not limited to, extracellular signal-regulated kinase
1/2 (ERK1/2), protein kinase B/Akt (Akt), p38 kinase
and c-Jun N-terminal kinase (JNK). ERK2 and Akt are
major mediators of external signals to internal events.
Others have shown that Akt and ERK2 contribute to the
regulation of VCAM-1 [9, 10]. Thus, we started our
studies examining these two kinases and their effects on
VCAM-1 expression. Here we report that the reduction
of ERK2 or Akt in rat aorta endothelial cells (RAEC) in-
creases insulin and TNFα-stimulated total VCAM-1 ex-
pression. In contrast, the simultaneous reduction of
both ERK2 and Akt did not cause an additive increase in
VCAM-1 protein above that of ERK2 or Akt alone. Al-
though there may not be a cumulative effect of increased
VCAM-1 due to the decreased presence of ERK2 and
Akt in endothelial cells, their diminished presence may
play a significant role in the inflammatory attributes of
cardiovascular disease.
Here we report that when the expression of ERK2 and
Akt was decreased via RNA interference, we observed
insulin and TNFα-stimulated increased VCAM-1 ex-
pression at the protein and cell surface level. However,
simultaneous downregulation of both ERK2 and Akt did
not show an additive or synergistic effect.
Methods
Materials
All general lab reagents were purchased from Sigma-
Aldrich (St. Louis, MO). PVDF membranes and other
Western blot accessories were from GE Healthcare/
Amersham (Piscataway, NJ). Primary rabbit antibodies
to ERK1/2 (9102), Akt (4056), and alpha-tubulin (2144S)
were from Cell Signaling (Boston, MA). The primary
rabbit antibody to VCAM-1 (NBP1-95622) was from
Novus Biologicals (Littleton, CO) and goat anti-rabbit-
secondary antibody IRDye680RD (926–68171) was from
LI-COR (Lincoln, NE). Rat aorta vascular endothelial
cells (RAEC) (CRL-1444) were from ATCC (Manassas, VA)
and culture medium was from Life Technologies (Grand
Island, NY). ERK2 (KR48780P) and Akt (KR45425P) short
hairpin (sh) RNA plasmids were obtained from SA
Biosciences/Qiagen (Valencia, CA). Transfection Medium
(108062) and Reagent ((108061) were from Santa Cruz
Biotechnology (Dallas, Tx). DyLight 488-conjugated
anti-VCAM-1 antibody was from Thermo Scientific
(Pittsburgh, PA). Four-well chamber slides were from
Thermo Fisher and DAPI Mounting Medium was from
Vector Labs (Burlingame, CA). Insulin (19278) was from
Sigma-Aldrich (St. Louis, MO) and TNFα (11271156001)
was from Roche (Indianapolis, IN).
Cell culturing
RAEC were cultured in complete growth medium
(CGM) [DMEM with 4 mM L-glutamine, 4.5 g/L-glu-
cose and 1.5 g/L sodium bicarbonate) and supplemented
with 10 % heat-inactivated fetal bovine serum (HI-FBS)
(10438–026) (Life Technologies, Grand Island, NY) and
1 % Antimycotic-Antibiotic solution (15240–062) (Life
Technologies) and cultured at 37 °C, 5 % CO2
atmosphere.
Preparation of shRNA stable cell lines
RAEC were grown to 50–70 % confluence in CGM
in 6-well culture plates. Cells were transfected with
shERK2 (clone #2) or shAkt (clone #2) inhibitory
plasmids as previously described [11]. Cells were in-
cubated in CGM containing 2 μg/mL of Puromycin
(Sigma-Aldrich) for 2–3 weeks for selection of
Puromycin resistant transformants.
Dual transfection of stable cell lines
To examine the effect of simultaneous ERK2 and Akt
knockdown on VCAM-1 expression, the ERK2 shRNA
stable cell line (ERK2 KD) was transiently transfected
with shAkt plasmid and the Akt shRNA stable cell line
(Akt KD) was transiently transfected with the shERK2
plasmid. These two protocols were carried out in order
to see if any difference occurred with respect to transfec-
tion sequence. Stable cell lines were transiently trans-
fected with shRNA plasmid DNA as described above
and incubated for 5 h with the DNA transfection mix.
Subsequently the transfection mix was aspirated and re-
placed with 2.0 mL CGM. Stimulation of cells by insulin
and/or TNFα occurred 48 h after transient transfection
was accomplished.
Stimulation of VCAM-1 expression
RAEC were cultured in CGM, whereas shRNA stable
cell lines (e.g., ERK2 KD and Akt KD) were cultured in
CGM containing 2 μg/mL Puromycin until assays were
performed. After incubating the transfected cells for an
additional 48 h, the cells were stimulated with or without
insulin (10 nM) and in the presence or absence of TNFα
(10 ng/mL) and evaluated for VCAM-1 expression as
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previously described [11]. Briefly, TNFα stimulation oc-
curred over a total of 6 h and cells activated with insulin
were stimulated for 1 h.
Western blot analysis
Sodium Dodecyl Sulfate Polyacrylamide Electrophoresis
was performed on cleared lysates. Western blot analysis
was subsequently performed as previously described,
[11] with the following differences. After completion of
protein transfer, membranes were washed in ultra-pure
water for 5 min. Membranes were then incubated in 3 %
non-fat milk (milk) in Tris-buffered Saline (TBS)
blocking solution for 1 h at room temperature and
then incubated with a designated primary antibody
solution (1:1000 in 3 % milk/TBS-T) overnight at 4 °C.
Membranes were washed 4 times with TBS plus Tween
(TBS-T) for 5 min at room temperature and then incu-
bated with a goat anti-rabbit secondary antibody (1:5000
in 3 % milk/TBS-T) conjugated to fluorochrome IR680RD
for 1 h at room temperature. Membranes were washed 4
times with TBS-T for 5 min at room temperature and then
incubated with a rabbit anti-tubulin primary antibody
solution (1:1000 in 3 % milk/TBS-T) for 3 h at room
temperature. After washing the membranes for 4 times
with TBS-T, the membranes were again incubated with a
goat anti-rabbit secondary antibody (1:5000 in 3 %
milk/TBS-T) conjugated to fluorochrome IR680RD for
1 h at room temperature. The membranes were
washed 4 times with TBS-T and allowed to dry before
performing densitometry. Densitometry was performed
using an Odyssey Licor system (Lincoln, NE). Alpha-
tubulin protein was used to normalize VCAM-1 signals.
Flow cytometry
Non-transfected RAEC were used as controls. Stably
transfected RAEC Akt knockdown (Akt KD) and ERK2
knockdown (ERK2 KD) cell lines were inoculated into 6-
well tissue culture dishes, transiently transfected with
shERK2 or shAkt plasmids, respectively, and stimulated
with insulin, TNFα, or combined insulin and TNFα as
described above in Dual Transfection. The cells were
washed twice with 2 mL of 1X PBS (Gibco). The PBS
was aspirated and 0.5 mL of Cell Dissociation Solution
Non-Enzymatic (Sigma-Aldrich) was added to each well.
After incubating the cells at 37 °C and 5 % CO2 for
30 min, 1 mL of 1 % Bovine Serum Albumin (BSA,
Sigma-Aldrich) in PBS was added to the cells and then
were gently triturated into a single cell suspension. The
cells were transferred to 5 mL Falcon polystyrene round
bottom tubes (Thermo Scientific) and centrifuged at 500
x g for 5 min. After aspirating the supernatants, the cells
were resuspended in 3 mL 1 % BSA, pelleted at 500 × g
by centrifugation, and the supernatants removed by
aspiration. The cells were resuspended in 200 μL of 1 %
BSA. Two microliters of DyLight 488-conjugated anti-
VCAM-1 antibody (Life Technologies, Grand Island
New York) were added to each tube and the cells were
resuspended by vortexing. The cells were incubated in
the dark for 30 min at room temperature. The cells were
centrifuged, washed twice with 3 mL 1 % BSA and re-
suspended in 200 μL of 1 % paraformaldehyde (PFA,
Electron Microscopy Sciences, Hatfield, PA). After incu-
bating the cells for 5 min at room temperature, the cells
were diluted with an additional 300 μL of PBS and ana-
lyzed using flow cytometry.
The experiments were run on a BD LSRII (BD Biosci-
ences, San Jose, CA). MFI and gating percentages as part
of data analysis were performed using BD FACSDiva v6
software.
Chamberslide cell preparation
2 × 105 of control RAEC, Akt KD or ERK2 KD stable
cell lines were plated in 1 mL of CGM in each well of a
4-well chamberslide and allowed to grow for 24 h, 37 °C
and 5 % CO2. The medium was aspirated and 1.0 mL of
fresh CGM was applied to the cells. Akt KD and ERK2
KD were either mock transfected, or transiently
Fig. 1 Insulin and TNFα increase expression of total VCAM-1 in rat
aorta endothelial cells over time. RAEC were cultured in Complete
Growth Medium (CGM) until 90 % confluent. Subsequently, cells
were stimulated for indicated times with insulin (10 nM) or TNFα
(10 ng/mL) alone or in combination. Total VCAM-1 protein was
determined by Western blot analysis. Analysis was performed by the
Licor Odyssey detection system. Total VCAM-1 is expressed as the
percent of controls and represents the mean ± SEM of six independent
experiments. *, P < 0.05 vs negative controls. **, P < 0.05 vs TNFα alone
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transfected with shERK2 or shAkt, respectively for 48 h.
Cells were then treated with either vehicle, 10 ng/mL
TNFα, insulin (10 nM) alone, or TNFα (10 ng/mL) and
then insulin (10 nM). The medium was aspirated and
the cells were washed three times with PBS and then in-
cubated in 400 μL of 4 % paraformaldehyde in PBS for
30 min. The medium was aspirated and washed three
times with 1 mL of PBS. The final PBS wash was aspi-
rated and 400 μL of a 1:1000 DyLight anti-VCAM-1
antibody soluton in 1 % BSA was added to each chamber
and incubated for 30 min at room temperature. The
cells were then washed three times with 500 μL of 1 %
BSA. The chamber walls were removed and one drop of
DAPI Mounting Medium was added to each group of
cells on the slide. Cells were then sealed with a glass
cover slip using clear nail polish. Slides were kept in a
dark refrigerator until microscopic visualization.
Confocal microscopy
A single, non-confluent monolayer of cells were im-
aged with a Leica TSC SP8X white light laser scan-
ning confocal microscope (Leica Microsystems GmbH.
Ernst-Leitz-Straße 17–37 Wetzlar, 35578 Germany).
Excitation of the DAPI channel was achieved using a
405 nm diode laser with an excitation intensity level
of 2.67 %. Emission signal was captured with standard
PMT Channel 1 with an emission gap of 430 nm -
480 nm. Excitation of ALexa fluor 488 utilized the
Leica Supercontinuum white light laser visible excita-
tion laser line (488 nm) and an intensity level of 3 %.
Emission signal was captured with Leica HyD 2 de-
tector (Hybird 2 PMT) with a with a set emission
gap of (505 nm - 555 nm). All image acquisitions
Fig. 2 Different clones of shRNA for Akt and ERK2 differentially
downregulate their respective proteins. Akt and ERK2 shRNA clones
provided by manufacturer were amplified in E. coli and isolated by
plasmid preparation. Individual clones of each shRNA were
transfected into different groups of RAEC as described in
Methods. (Panel a) Akt and ERK2 proteins were quantified in
unstimulated cells by Western blot analysis in untreated cells. “0”
is negative control clone, and numbers 1–4 are different clones
provide by the manufacturer. Intensity of bands are proportional
to expression of designated protein in the presence of each
shRNA clone. (Panel b) Relative protein expression is compared
to controls (negative control clone)
Fig. 3 RAEC transfected with shERK2 (clone #2) and then stimulated
with insulin or TNFα alone or in combination demonstrates the
negative regulation of ERK2 in VCAM-1 expression. RAEC were stably
transfected with shERK2 (ERK2 KD) and then stimulated with insulin
(10 nM, 1 h) or TNFα (10 ng/mL, 6 h) alone or in combination. Total
VCAM-1 protein was analyzed by SDS-PAGE and determined by
Western blot analysis. (Upper Panel) “NST”, cells not stimulated with
insulin or TNFα. “Ins” cells stimulated with insulin. “TNFα” cells
stimulated with TNFα. “C” control cells not transfected with
shRNA, while “sh” cells were transfected with shERK2. (Lower
Panel) “C” control RAEC not transfected (open bars). ERK2 KD are
RAEC stably transfected with shERK2 (black bars). “NST” cells not
stimulated with insulin or TNFα. Total VCAM-1 is expressed as
the percent of controls and represents the mean ± SEM of six
independent experiments. Alpha-tubulin was used to normalize
VCAM-1 profiles. *, P < 0.05 vs non-stimulated cells
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were carried out using the Leica Application Suite X
(version 1.1.0.12420, LASX AF).
Data analysis
Data were analyzed by either unpaired Student’s t test
(two groups) or ANOVA with subsequent Tukey posttest
(several groups) as indicated. A “P” value of less
than 0.05 was considered significant. Results were
expressed as the mean ± SEM of three or more inde-
pendent experiments.
Results
Both insulin and TNFα significantly (P < 0.05) increased
VCAM-1 at 6 h as compared to controls (Fig. 1). TNFα
stimulated VCAM-1 was significantly (P < 0.05) greater
than that seen for insulin alone at 2 and 6 h time points.
Interestingly, cells stimulated with insulin plus TNFα for
6 h increased VCAM-1 significantly (P < 0.05) greater
than that seen for insulin or TNFα alone.
In order to tease out the intracellular kinase regulators
of these events, we incorporated RNA interference into
these experiments to better understand which kinases
were mediating the external signals of insulin and TNFα
with regards to the expression of VCAM-1 protein.
In previous studies, we investigated the effect of ERK5
knockdown on insulin and TNFα-stimulated VCAM-1
[11]. In those studies, decreased ERK5 resulted in de-
creased insulin and TNFα-stimulated VCAM-1 expres-
sion. To continue this line of study we measured the
expression of VCAM-1 in vascular cells in which expres-
sion of either ERK2 or Akt or both were decreased using
RNAi techniques and in the presence of insulin and/or
TNFα.
After first determining which shERK2 and shAkt plas-
mid clone decreased its respective kinase most signifi-
cantly (Fig. 2), we transfected the most efficacious
shERK2 plasmid clone (#2) into our cells and treated
with either insulin (10 nM) or TNFα (10 ng/mL) alone
Fig. 4 RAEC transfected with shAkt (clone #2) and then stimulated
with insulin or TNFα alone or in combination demonstrates the
negative regulation of Akt in VCAM-1 expression. REAC were stably
transfected with shAkt (Akt KD) and then stimulated with insulin
(10 nM, 1 h) or TNFα (10 ng/mL, 6 h) alone or in combination. Total
VCAM-1 protein was analyzed by SDS-PAGE and determined by
Western blot analysis. (Upper Panel) “NST”, cells not stimulated with
insulin or TNFα. “Ins” cells stimulated with insulin. “TNFα” cells
stimulated with TNFα. “C” control RAEC not transfected with
shRNA, while “sh” cells were transfected with shAkt. (Lower
Panel) “C” control RAEC not transfected (open bars). Akt KD are
RAEC stably transfected with shAkt (black bars). “NST” cells not
stimulated with insulin or TNFα. Total VCAM-1 is expressed as
the percent of controls and represents the mean ± SEM of six
independent experiments. Alpha-tubulin was used to normalize
VCAM-1 profiles. *, P < 0.05 vs non-stimulated cells
Fig. 5 RAEC transfected with shAkt and shERK2 and then stimulated
with insulin or TNFα alone or in combination exhibit increased
VCAM-1 protein expression greater than stimulated, mock transfected
cells, but not greater than cells transfected with shAkt alone. RAEC
were stably transfected with shAKT and then transiently transfected
with shERK2. Subsequently, cells were stimulated with insulin (10 nM,
1 h) or TNFα (10 ng/mL, 6 h) or in combination. (Upper Panel) C,
control RAEC, no shRNA. A, cells transfected with shAkt alone. AE, cells
stably transfected with shAkt and then transiently transfected with
shERK2. (Lower Panel) Open bars are control cells not transfected.
Stippled bars (Akt KD) RAEC stably transfected with shAkt. Black bars
(Akt KD + shERK2) RAEC stably transfected with shAkt and transiently
transfected with shERK2. “NST”, cells not stimulated with insulin or
TNFα. Total VCAM-1 is expressed as fold increase above negative
controls and represents the mean ± SEM of five independent
experiments. Alpha-tubulin was used to normalize VCAM-1 profiles. #,
P < 0.05 verses non-stimulated controls. *, P < 0.05 versus stimulated
controls of similar treatment group without shRNA
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or in combination for designated times. Subsequently,
we measured the change in total VCAM-1 protein be-
tween positive controls (no shRNA) and ERK2 KD cells.
Interestingly, in the ERK2 KD cells, insulin-stimulated
VCAM-1 increased 52 % above positive controls (cells
treated with insulin with no shERK2) and TNFα-alone
stimulated VCAM-1 84 % above positive controls
(TNFα- stimulated cells with no shERK2) (Fig. 3). In
ERK2 KD cells, VCAM-1 continued to increase 96 %
above combined insulin plus TNFα-stimulated positive
controls.
We next determined whether shAkt affected insulin
and TNFα-stimulated VCAM-1 expression. Similar to
the results observed with ERK2 cells, the presence of
shAkt (Akt KD) significantly increased VCAM-1 in the
presence of insulin or TNFα alone 3.8-fold and 2.7-fold,
respectively, above positive controls (cells not transfected
with shRNA) (Fig. 4). In the presence of combined insulin
and TNFα, Akt KD cells exhibited a 2.6-fold increase in
VCAM-1 above positive controls cells treated with insulin
and TNFα.
Next, we were interested in changes in VCAM-1 ex-
pression in cells stimulated with insulin and/or TNFα
and double transfected with shAkt and then shERK2.
First, RAEC were stably transfected with shAkt (2 weeks
before treatment) and then transiently transfected with
shERK2 48 h before insulin and TNFα treatment.
Interestingly, Akt KD cells transiently transfected with
Fig. 6 RAEC transfected with shERK2 and shAkt and then stimulated
with insulin or TNFα alone or in combination exhibit increased
VCAM-1 protein expression greater than stimulated mock transfected
cells, but not greater than cells transfected with one shERK2 alone.
RAEC were stably transfected with shERK2 and then transiently trans-
fected with shAkt. Subsequently, cells were stimulated with insulin
(10 nM, 1 h) or TNFα (10 ng/mL, 6 h) or in combination. (Upper
Panel) C, control RAEC, no shRNA. E, cells transfected with shERK2
alone. EA, cells stably transfected with shERK2 and then transiently
transfected with shAkt. (Lower Panel) Open bars are control cells not
transfected. Stippled bars (ERK2 KD) RAEC stably transfected with
shERK2. Black bars (ERK2 KD + shAkt) RAEC stably transfected with
shERK2 and transiently transfected with shAkt. “NST”, cells not stimu-
lated with insulin or TNFα. Total VCAM-1 is expressed as fold in-
crease above negative controls and represents the mean ± SEM of
five independent experiments. Alpha-tubulin was used to normalize
VCAM-1 profiles. #, P < 0.05 verses non-stimulated controls. *, P < 0.05
versus stimulated controls of similar treatment group without shRNA
Fig. 7 RAEC transfected with shAkt and shERK2 exhibit increased
insulin and TNFα-stimulated VCAM-1 at the cell surface as determined
by flow cytometery. (Panel a) RAEC were stably transfected with shAkt
(Akt KD) or (Panel b) shERK2 (ERK2 KD) and then transiently transfected
with shERK2 or shAkt, respectively. Subsequently, cells were stimulated
without or with insulin (10 nM) or TNFα (10 ng/mL) or in combination
and surface VCAM-1 was determined by flow cytometry. C,
non-transfected RAEC (no shRNA). NST, no stimulation. Akt KD,
stable cell lines with shAkt. ERK2 KD, stable cell lines with shERK2. Akt
KD + shERK2, stable shAkt cells lines transiently transfected with shERK2.
ERK2 KD + shAkt, stable cell lines with shERK2 transiently transfected
with shAkt. Surface VCAM-1 is expressed as percent of respective
controls (not stimulated, No Stim) and represents the mean ± SEM of
five independent experiments. *, P < 0.05 compared to their respective
unstimulated controls. #, P < 0.05 compared to stimulated
non-transfected controls
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shERK2 exhibited no increases in insulin or TNFα stim-
ulated VCAM-1 significantly greater than that seen in
Akt KD cells alone (Fig. 5).
We wanted to see if altering the sequence of trans-
fected shRNA would affect the outcome of VCAM-1 ex-
pression. In experiments similar to those depicted in
Fig. 5, we stably transfected RAEC with shERK2, waited
2 weeks and then transiently transfected the cells with
shAkt. Similar to the experiments in which shAkt was
stably expressed, ERK2 KD expressing transiently trans-
fected shAkt and stimulated with either insulin or TNFα
alone or in combination did exhibit increased VCAM-1
above positive controls (no shRNA) (Fig. 6). However,
similar to that observed in Fig. 5, expression of VCAM-
1 was not significantly greater in ERK2 KD cells transi-
ently transfected with shAkt as compared to ERK2 KD
cells alone.
Finally, we wanted to determine whether increased
VCAM-1 at the total cellular protein level equated to
increases at the cell surface. We used two different pro-
cedures to determine changes in VCAM-1 at the cell
surface: flow cytometry and confocal microscopy. Using
flow cytometry, both the Akt KD and ERK2 KD cell lines
exibited significantly (P < 0.05) greater expression of
VCAM-1 at the surface in the presence of insulin and/or
TNFα than cells mock transfected (Fig. 7). In order to
visualize the increases in VCAM-1 at the cell surface,
we utilized confocal microscopy and again observed
increased VCAM-1 at the cell surface in Akt KD and
ERK2 KD cell lines (Fig. 8).
Discussion
DM is a pervasive disease that affects old and young
alike, and is followed by a sequala of effects. Cardiovas-
cular disease and atherosclerosis are major players in the
insidious repertoire of DM and their existence is based
upon increased amounts of, but not limited to, serum
insulin and TNFα. In turn, these biomoleculer signals
escalate downstream cellular events such as increased
expression of VCAM-1. Equally important are the kinase
mediators that transduce the serum and cell surface sig-
nals of insulin and TNFα to intracellular events. ERK2
and Akt are members of this large kinase family and al-
though they may not be the only intracellular mediators
of these external signals, they appear to be conduits of
inflammatory regulation within endothelial cells.
Kinases such as ERK2 and Akt are major players in
intracellular signaling [12]. Down regulation of one may
have profound effects in intracellular events [13–16].
Loss of positive effectors or negative inhibitors may
cause unknown effects in the cell and the vasculature.
The loss of positive players may cause decreases in
positive-regulation of key pathways, thereby decreasing
their beneficial effects. Alternatively, the loss of negative
effectors (i.e., inhibitors) may cause the loss of negative-
regulation in the same or parallel pathways. In the
Fig. 8 RAEC transfected with shAkt and shERK2 exhibit increased insulin and TNFα-stimulated cell surface VCAM-1 as determined by confocal
microscopy. RAEC were plated and stimulated as described in Methods. Surface VCAM-1 was detected by immunocytochemistry as described in
Methods and visualized by confocal microscopy. CON, RAEC controls, no shRNA; No Stim, no stimulation by insulin or TNFα; Akt KD, stable cell
lines transfected with shAkt. ERK2 KD, stable cell lines transfected with shERK2. shAkt, cells transiently transfected with shAkt. shERK2, cells transiently
transfected with shERK2. Scale bar is 50 μm
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current report, knock-down of ERK2 and Akt appeared to
perturb the physiologic (inhibitory) qualitiy of these ki-
nases, eliciting an upregulation of VCAM-1. Interestingly,
decreased expression of both ERK2 and Akt did not have
an additive or synergistic effect. This may mean that they
are in the same regulatory pathway or other effectors are
regulating the expression of VCAM-1 as well.
The down-regulation of ERK2 and Akt in our study
significantly (P < 0.05) increased VCAM-1 in cells
treated with both insulin and TNFα: a possible scenario
in the atherosclerotic vasculature. Kinases are part of
common, intracellular pathways that appear to “cross-
talk” within the cell [17]. The concert of these signals
may keep downstream events in check, whereas their
pertubations may cause unbeknownst effects.
Inflammation is associated with many diseases such
as obesity, cancer, autoimmunity and atherosclerosis
[18–22]. The essential cellular events that initiate the
inflammatory process in the vasculature are extracellular
signals. They in turn act on cell surface receptors and
instigate intracellular signaling via the kinases. It is these
kinases that are instrumental in upregulating the inflam-
matory markers such as VCAM-1 [23, 24].
Interestingly, other studies have established that pro-
inflammatory cytokines such as IL-1β are upregulated by
VCAM-1 expression [25]. It will be very interesting to
determine if TNFα is upregulated by VCAM-1 at the
monocyte as well. If this does occur a positive feed-
forward mechanism is possible.
Here we report that not only did insulin and TNFα
stimulate the expression of VCAM-1, but also that dre-
creased expression of ERK2 and Akt resulted in in-
creased expression of VCAM-1 at the total protein and
cell surface level. Our future studies will evaluate the ex-
pression of VCAM-1 in the presence of other inhibitory
RNAs; in particular, p38 and JNK. Both p38 and JNK
have been shown to be involved with inflammation. Ob-
viously, the knock-down of these two kinases and their
effects on VCAM-1 expression will be very interesting
and will add to the “cross-talk” picture of the cell. These
current and future studies will benefit strategies that will
assist in decreasing the inflammatory effects of athero-
sclerosis in the vasculature.
Conclusions
Insulin and TNFα increased VCAM-1 expression in
RAEC. Yet, RAEC transfected with shAkt and shERK2,
which cause decreased expression of Akt and ERK2, ini-
tiated increases in total and cell surface VCAM-1 pro-
tein in the presence of insulin and/or TNFα greater that
seen in mock transfected cells.
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